1. MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma. Gramantieri L, et al. Cancer Res 2020. 80:1720-34.
2. The epigenetically regulated miR-494 associates with stem cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Pollutri D, et al. Cell Death Dis 2018. 9(1):4.
3. In hepatocellular carcinoma miR-221 modulates Sorafenib resistance through inhibition of caspase-3 mediated apoptosis. Fornari F, et al. Clin Cancer Res 2017. 23:3953-65.
4. The metabolic gene HAO2 is down regulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival. Mattu S*, et al. J Hepatol 2016. 64:891-898.
5. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. Fornari F, et al. PLoS ONE 2015. 10:e0141448.
6. In hepatocellular carcinoma miR-519d is upregulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. Fornari F, et al. J Pathol 2012. 227:275-85.
7. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Fornari F, et al. Cancer Res 2010. 70: 5184-93. IF 8.234
8. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Fornari F, et al. Cancer Res 2009. 69:5761-67.
9. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Fornari F, et al. Oncogene 2008. 27:5651-61.
10. Cyclin G1 is target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Gramantieri L, et al. Cancer Res 2007. 67:6092-99.